Recent reports indicated that cetuximab treatment induces HER3 activation in cancers 54, 55, and dual targeting of the EGFR and HER3 can overcome acquired resistance to cetuximab or the EGFR tyrosine kinase inhibitor (TKI), erlotinib, further highlighting the role of HER3 in EGFR-targeted therapy 55, 56. This evidence concerns the gene ERBB3 and cancer.